Author/Authors :
Parissis، نويسنده , , John T. and Panou، نويسنده , , Fotios and Farmakis، نويسنده , , Dimitrios and Adamopoulos، نويسنده , , Stamatis and Filippatos، نويسنده , , Gerasimos and Paraskevaidis، نويسنده , , Ioannis and Venetsanou، نويسنده , , Koula and Lekakis، نويسنده , , John and Kremastinos، نويسنده , , Dimitrios Th.، نويسنده ,
Abstract :
In this randomized, placebo-controlled study, it was found that a 24-hour levosimendan infusion improves echocardiographic markers of abnormal left ventricular diastolic function (transmitral flow patterns and mitral annulus velocities, as assessed by transthoracic pulse-wave Doppler and tissue Doppler imaging, respectively) and reduces substances of excessive neurohormonal activation (plasma B-type natriuretic peptide and interleukin-6) in patients with advanced heart failure. Moreover, levosimendan-treated patients had fewer events and longer progression-free survival during a 5-month follow-up compared with those who received placebo. Thus, levosimendan seems to be effective in improving left ventricular diastolic function and reducing neurohormonal activation in patients with severe heart failure.
